Sulfadiazine Ice Yellow Tablets

Sulfadimethoxazole (SMZ) and trimethoprim (TMP) have synergistic antibacterial or bactericidal effects, because sulfa drugs act on dihydrofolate synthase, interfering with the first step of folic acid synthesis, while trimethoprim acts on the second step of folic acid anabolism, selectively inhibiting dihydrofolate reductase. Therefore, the combination of the two can double-block the folic acid metabolism of bacteria. The synergistic antibacterial effect of the two is enhanced compared to the use of a single drug, and the number of drug-resistant strains is reduced.

This product is a compound preparation, and its components are: each tablet contains 300 mg of sulfamethoxazole, 60 mg of trimethoprim, 30 mg of artificial bezoar and 5 mg of borneol.

This product is a green diamond-shaped film-coated tablet, which appears light orange-yellow when the film coating is removed.

Used for tonsillitis, bronchitis, enteritis, dysentery, urinary tract infection, etc.

Oral administration. 1-2 tablets at a time, twice a day. Or as directed by your doctor.

1. Adverse reactions of sulfamethoxazole ⑴ Allergic reactions are common and may manifest as drug eruptions. In severe cases, exudative erythema multiforme, exfoliative dermatitis, and bullous epidermolysis atrophic dermatitis may occur; there are also serum sickness-like reactions such as photosensitivity reactions, drug fever, joint and muscle pain, and fever. Anaphylactic shock is occasionally seen. ⑵ Neutropenia or deficiency, thrombocytopenia, and aplastic anemia. Patients may present with sore throat, fever, pallor, and bleeding tendency. ⑶ Hemolytic anemia and hemoglobinuria. This is prone to occur in patients who lack glucose-6-phosphate dehydrogenase after the use of sulfonamides, and is more common in newborns and children than in adults. ⑷ Hyperbilirubinemia and neonatal kernicterus. Because this product competes with bilirubin for protein binding sites, it can cause an increase in free bilirubin. Neonatal liver function

1. It is contraindicated for patients with severe renal impairment; 2. It is contraindicated for patients who are allergic to sulfonamides; 3. It is contraindicated for patients with megaloblastic anemia; 4. It is contraindicated for infants under 2 months old; 5. It should be used with caution by pregnant women.

Precautions for children: It is forbidden for infants under 2 months old. Precautions for pregnancy and lactation: Pregnant women should use with caution. Precautions for the elderly: Elderly patients have an increased chance of serious adverse reactions when using sulfonamides. Severe rash, bone marrow suppression and thrombocytopenia are common serious adverse reactions in the elderly. Therefore, elderly patients should avoid using it. If there is an indication, the decision should be made after weighing the pros and cons.

1. Sulfamethoxazole: ⑴ The simultaneous use with urine alkalinizing drugs can enhance the solubility of sulfonamides in alkaline urine and increase excretion. ⑵ Para-aminobenzoic acid can replace sulfonamides and be taken up by bacteria, thus antagonizing the antibacterial effect of sulfonamides. The two should not be used together. ⑶ When the following drugs are used together with sulfonamides, the latter can replace the protein binding sites of these drugs, or inhibit their metabolism, resulting in prolonged drug action or toxicity. Therefore, when these drugs are used after sulfonamides, their dosages need to be adjusted. Such drugs include oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium and thiopental sodium. ⑷ When bone marrow suppressive drugs are used together with sulfonamides, the adverse reactions of such drugs on the hematopoietic system may be enhanced. If there is an indication for the simultaneous use of two types of drugs, possible toxic reactions should be closely observed. ⑸ Avoid

seal.

Compound

36 months

Youcare Pharmaceutical Group Co., Ltd.

• Founded in:

  2001-08-14

• Address:

  No. 6, Hongda Middle Road, Beijing Economic and Technological Development Zone, Beijing

• Tax NO.:

  911100007263731643

• Registered Funds:

  450 million yuan

• Website:

  Log in to view

• Email:

  Log in to view